A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic modelCraig H. Moskowitz, Joachim Yahalom, Jing Qin et al.|Blood|2001Cited by 427
Ifosfamide, Carboplatin, and Etoposide: A Highly Effective Cytoreduction and Peripheral-Blood Progenitor-Cell Mobilization Regimen for Transplant-Eligible Patients With Non-Hodgkin's LymphomaCraig H. Moskowitz, Andrew D. Zelenetz, Joseph R. Bertino et al.|Journal of Clinical Oncology|1999Cited by 303
Intensive chemotherapy with cyclophosphamide, doxorubicin, high‐dose methotrexate/ifosfamide, etoposide, and high‐dose cytarabine (CODOX‐M/IVAC) for human immunodeficiency virus–associated Burkitt lymphomaEunice S. Wang, Ariela Noy, David J. Straus et al.|Cancer|2003Cited by 151
High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysisTarun Kewalramani, Craig H. Moskowitz, Andrew D. Zelenetz et al.|Blood|2000Cited by 120
74 | A MULTICENTER PHASE II STUDY OF GLOFITAMAB PLUS POLATUZUMAB‐R‐CHP FOR PATIENTS WITH HIGH‐RISK DIFFUSE LARGE B‐CELL LYMPHOMAJennifer L. Crombie, Juan Pablo Alderuccio, Robert Redd et al.|Hematological Oncology|2025Cited by 3